Favrille Drug Misses Secondary Target
13th Nov 2006, 16:41 GMT
Favrille said its non-Hodgkin's lymphoma drug missed the secondary endpoint of a late-stage clinical trial, but the biopharmaceutical company is still tracking data related to the primary endpoint.
Favrille Drug Misses Secondary Target related news:
- Favrille drug fails secondary goal — Pharmaceutical Business Review Latest News
- Favrille Announces Interim Analysis Of Secondary Endpoint From Pivotal Phase 3 Clinical Trial Of FavId Following Rituxan — Health News from Medical News Today
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma — Bio-Technology News from StratCenter.com
- Favrille 3Q Loss Widens on Costs — StratWire - Business of Healthcare NewsFeed
- Favrille Reports Q3 2006 Financial Results — StratWire - Business of Healthcare NewsFeed
- 'UK FBI' fails to hit asset target — Scotsman.com News - UK
- Dealzmodo: 10% Off at Target.com — Gizmodo
- AHA: Women Receive Less Cardiovascular Secondary Prevention — MedPage Today Cardiovascular
- Guidelines on Secondary Prevention of Ischemic Stroke — Medscape Med Students Headlines
- A Target store in a Denver suburb in a file phtoto. Target reported ... — Business Photos - Reuters on Yahoo! News Photos
Latest news from Pharmaceuticals News from StratCenter.com:
- Spectrum Pharmaceuticals to Receive $5 mln Milestone Payment From PAR Pharmaceutical for Sumatriptan Injection
- Medco to Present at the Credit Suisse Annual Healthcare Conference
- Bob Dole Medicare Podcast Helps Seniors through 2007 Drug Coverage Enrollment Process
- Unique Sugar Improves Energy, Pain and Quality of Life in Fibromyalgia and Chronic Fatigue Patients!
- Care Clinic Purchases Pinnacle Easy Care
- Pegasystems Enhances 2 Business Critical BPM Frameworks for the Healthcare Industry
- Isis Cholesterol Drug Shown Effective
- Taro Receives Marketing Authorization in UK for Etopan XL Tablets 600 mg, Etodolac
- Nymox Reports Q3 2006 Financial Results
- RemoteMDx Raises $6 mln in Private Placement